oxotremorine has been researched along with Idiopathic Parkinson Disease in 8 studies
Oxotremorine: A non-hydrolyzed muscarinic agonist used as a research tool.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Parkinson disease is a neurodegenerative disorder whose symptoms are caused by the loss of dopaminergic neurons innervating the striatum." | 1.33 | RGS4-dependent attenuation of M4 autoreceptor function in striatal cholinergic interneurons following dopamine depletion. ( Chen, S; Ding, J; Ebert, PJ; Goldberg, JA; Guzman, JN; Hamm, HE; Levitt, P; Surmeier, DJ; Tkatch, T; Wilson, CJ, 2006) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 6 (75.00) | 18.7374 |
| 1990's | 1 (12.50) | 18.2507 |
| 2000's | 1 (12.50) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ding, J | 1 |
| Guzman, JN | 1 |
| Tkatch, T | 1 |
| Chen, S | 1 |
| Goldberg, JA | 1 |
| Ebert, PJ | 1 |
| Levitt, P | 1 |
| Wilson, CJ | 1 |
| Hamm, HE | 1 |
| Surmeier, DJ | 1 |
| Kehr, W | 1 |
| Kinoshita, H | 1 |
| Hasegawa, T | 1 |
| Katsumata, Y | 1 |
| Kameyama, T | 1 |
| Yamamoto, I | 1 |
| Nabeshima, T | 1 |
| Tang, LC | 1 |
| Cotzias, GC | 1 |
| Brossi, A | 1 |
| Pool, W | 1 |
| Sheppard, H | 1 |
| Burns, JJ | 1 |
| Kaiser, A | 1 |
| Bigler, R | 1 |
| Bartholini, G | 1 |
| Pletscher, A | 1 |
| Brown, DM | 1 |
| Hughes, BO | 1 |
| Marsden, CD | 1 |
| Meadows, JC | 1 |
| Spicer, B | 1 |
| Borgman, RJ | 1 |
| Mcphillips, JJ | 1 |
| Stitzel, RE | 1 |
| Goodman, IJ | 1 |
| Pálosi, E | 1 |
| Szporny, L | 1 |
1 trial available for oxotremorine and Idiopathic Parkinson Disease
| Article | Year |
|---|---|
Some initial animal and human pharmacological studies with benapryzine (BRL 1288).
Topics: Acetylcholine; Aged; Animals; Antiparkinson Agents; Benzilates; Clinical Trials as Topic; Dose-Respo | 1973 |
7 other studies available for oxotremorine and Idiopathic Parkinson Disease
| Article | Year |
|---|---|
RGS4-dependent attenuation of M4 autoreceptor function in striatal cholinergic interneurons following dopamine depletion.
Topics: Acetylcholine; Action Potentials; Animals; Autoreceptors; Calcium Channels; Cell Communication; Corp | 2006 |
[Drug therapy of Parkinson disease and parkinson disease-like symptoms].
Topics: Adenylyl Cyclases; Animals; Aromatic-L-Amino-Acid Decarboxylases; Biperiden; Brain; Catechol O-Methy | 1981 |
Effect of dizocilpine (MK-801) on the catalepsy induced by delta 9-tetrahydrocannabinol in mice.
Topics: Acetylcholine; Animals; Catalepsy; Disease Models, Animal; Dizocilpine Maleate; Dopamine; Dronabinol | 1994 |
Modification of the actions of some neuroactive drugs by growth hormone.
Topics: Animals; Apomorphine; Behavior, Animal; Dihydroxyphenylalanine; Dopamine; Drug Synergism; Growth Hor | 1976 |
L-DOPA: chemical modifications and biological evaluation.
Topics: Animals; Antiparkinson Agents; Blepharoptosis; Catatonia; Disease Models, Animal; Humans; Hypothermi | 1974 |
Synthesis and pharmacology of centrally acting dopamine derivatives qnd analogs in relation to parkinson's disease.
Topics: Acetylation; Alkylation; Animals; Body Temperature; Chemical Phenomena; Chemistry; Dopamine; Hydroly | 1973 |
Effect of gamma-hydroxybutyric acid on tremor induced oxotremorin.
Topics: Animals; Atropine; Brain Chemistry; Disease Models, Animal; Drug Antagonism; Drug Synergism; Female; | 1972 |